The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).
 
Masanori Terashima
Honoraria - Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst)
 
Kazuhiro Yoshida
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Johnson & Johnson (Inst); KCI (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
 
Sun Young Rha
No Relationships to Disclose
 
Jae Moon Bae
No Relationships to Disclose
 
Guoxin Li
No Relationships to Disclose
 
Hitoshi Katai
Honoraria - Chugai Pharma; Covidien/Medtronic; Lilly Japan; Taiho Pharmaceutical
 
Masahiko Watanabe
No Relationships to Disclose
 
Yasuyuki Seto
No Relationships to Disclose
 
Han-Kwang Yang
No Relationships to Disclose
 
Jiafu Ji
No Relationships to Disclose
 
Hideo Baba
Speakers' Bureau - Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Satoshi Morita
No Relationships to Disclose
 
Masahiko Nishiyama
Research Funding - Yakult Honsha